GSK: Bepirovirsen Accepted for Review by the European Medicines Agency as a Potential First-In-Class Treatment for Chronic Hepatitis B
March 28, 2026
March 28, 2026
LONDON, England, March 28 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on March 27, 2026:
* * *
Bepirovirsen accepted for review by the European Medicines Agency as a potential first-in-class treatment for chronic hepatitis B
- Submission supported by statistically significant and clinically meaningful functional cure rates in pivotal PhIII B-Well trials.
- Nearly 3.2 million people in Europe . . .
* * *
Bepirovirsen accepted for review by the European Medicines Agency as a potential first-in-class treatment for chronic hepatitis B
- Submission supported by statistically significant and clinically meaningful functional cure rates in pivotal PhIII B-Well trials.
- Nearly 3.2 million people in Europe . . .